Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at Two Investor Conferences in November

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that members of Recludix’s...
September 11, 2025 16:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation Forum

SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.,...
July 14, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer

--Brian Hodous, Ph.D., promoted to chief scientific officer -- Vivek Kadambi, Ph.D., joins Recludix as senior vice president of non-clinical sciences and CMC -- Kristin Polsenski, M.B.A., expands...
June 02, 2025 07:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that...
May 19, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

--Efficacy comparable to anti-IL4/IL13 antibody control --Achieved dose-dependent and durable target modulation in vivo without requiring degradation of STAT6 protein --Avoided broad JAK-mediated...
May 07, 2025 12:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria

-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU)-- BTK inhibition through the SH2 domain results in...
February 10, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.,...
January 10, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.,...
November 25, 2024 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Participate in Two Investor Conferences in December

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced that members of Recludix’s...
November 14, 2024 10:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis

-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis -STAT3 inhibition does not impair the...